281 related articles for article (PubMed ID: 25755489)
41. Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.
Tredger JM; Brown NW; Dhawan A
Drugs; 2008; 68(10):1385-414. PubMed ID: 18578558
[TBL] [Abstract][Full Text] [Related]
42. Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients.
Manzia TM; Angelico R; Ciano P; Mugweru J; Owusu K; Sforza D; Toti L; Tisone G
World J Gastroenterol; 2014 Sep; 20(34):12217-25. PubMed ID: 25232255
[TBL] [Abstract][Full Text] [Related]
43. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
Charlton M; Seaberg E
Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S107-14. PubMed ID: 10431024
[TBL] [Abstract][Full Text] [Related]
44. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
45. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
[TBL] [Abstract][Full Text] [Related]
46. Calcineurin inhibitor minimization protocols in liver transplantation.
Farkas SA; Schnitzbauer AA; Kirchner G; Obed A; Banas B; Schlitt HJ
Transpl Int; 2009 Jan; 22(1):49-60. PubMed ID: 19121146
[TBL] [Abstract][Full Text] [Related]
47. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
Thieme CJ; Schulz M; Wehler P; Anft M; Amini L; Blàzquez-Navarro A; Stervbo U; Hecht J; Nienen M; Stittrich AB; Choi M; Zgoura P; Viebahn R; Schmueck-Henneresse M; Reinke P; Westhoff TH; Roch T; Babel N
Kidney Int; 2022 Dec; 102(6):1392-1408. PubMed ID: 36103953
[TBL] [Abstract][Full Text] [Related]
48. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD010253. PubMed ID: 24901467
[TBL] [Abstract][Full Text] [Related]
49. Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors.
Barbier L; Garcia S; Cros J; Borentain P; Botta-Fridlund D; Paradis V; Le Treut YP; Hardwigsen J
J Hepatol; 2013 Dec; 59(6):1223-30. PubMed ID: 23933266
[TBL] [Abstract][Full Text] [Related]
50. Calcineurin inhibitor-free protocols: risks and benefits.
Barbari AG; Stephan AG; Masri MA
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
[TBL] [Abstract][Full Text] [Related]
51. Review on immunosuppression in liver transplantation.
Moini M; Schilsky ML; Tichy EM
World J Hepatol; 2015 Jun; 7(10):1355-68. PubMed ID: 26052381
[TBL] [Abstract][Full Text] [Related]
52. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
Guerra G; Srinivas TR; Meier-Kriesche HU
Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
[TBL] [Abstract][Full Text] [Related]
53. Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients.
Walsh C; Barkun J; Tchervenkov J; Deschenes M; Ghali P; Wong P; Chaudhury P; Paraskevas S; Metrakos P; Cantarovich M
Transplantation; 2013 Feb; 95(3):495-500. PubMed ID: 23296149
[TBL] [Abstract][Full Text] [Related]
54. Immunosuppressive therapies after heart transplantation--The balance between under- and over-immunosuppression.
Söderlund C; Rådegran G
Transplant Rev (Orlando); 2015 Jul; 29(3):181-9. PubMed ID: 25812489
[TBL] [Abstract][Full Text] [Related]
55. De-novo calcineurin-inhibitor-free immunosuppression with sirolimus and mycophenolate mofetil after heart transplantation: 5-year results.
Meiser B; Buchholz S; Kaczmarek I
Curr Opin Organ Transplant; 2011 Oct; 16(5):522-8. PubMed ID: 21836511
[TBL] [Abstract][Full Text] [Related]
56. Immunosuppression in Liver Transplantation: State of the Art and Future Perspectives.
Nedredal GI; Picon RV; Chedid MF; Foss A
Curr Pharm Des; 2020; 26(28):3389-3401. PubMed ID: 32520679
[TBL] [Abstract][Full Text] [Related]
57. Current concepts and perspectives of immunosuppression in organ transplantation.
Scherer MN; Banas B; Mantouvalou K; Schnitzbauer A; Obed A; Krämer BK; Schlitt HJ
Langenbecks Arch Surg; 2007 Sep; 392(5):511-23. PubMed ID: 17450373
[TBL] [Abstract][Full Text] [Related]
58. Steroid or calcineurin inhibitor-sparing immunosuppressive protocols.
Grinyó JM; Cruzado JM
Contrib Nephrol; 2005; 146():30-42. PubMed ID: 15567918
[TBL] [Abstract][Full Text] [Related]
59. Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation.
Asleh R; Alnsasra H; Habermann TM; Briasoulis A; Kushwaha SS
Front Cardiovasc Med; 2022; 9():787975. PubMed ID: 35282339
[TBL] [Abstract][Full Text] [Related]
60. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
Steigerwalt SP; Brar N; Dhungel A; Butcher D; Steigerwalt S; El-Ghouroury M; Provenzano R
Transplant Proc; 2009 Dec; 41(10):4184-7. PubMed ID: 20005365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
